IL-8 Promotes Cell Migration Through Regulating EMT by Activating the Wnt/β-catenin Pathway in Ovarian Cancer

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2019 Dec 4

PMID 31793192

Citations 42

Authors

Jirui Wen

Zhiwei Zhao

Liwei Huang

Ling Wang

Yali Miao

Jiang Wu

Affiliations

Soon will be listed here.

Abstract

Interleukin-8 (IL-8), as an inflammatory chemokine, has been previously shown to contribute to tumorigenesis in several malignancies including the ovarian cancer. However, little is known about how IL-8 promotes the metastasis and invasion of ovarian cancers cells. In this study, we found that IL-8 and its receptors CXCR1 and CXCR2 were up-regulated in advanced ovarian serous cancer tissues. Furthermore, the level of IL-8 and its receptors CXCR1 and CXCR2 expression were associated with ovarian cancer stage, grade and lymph node metastasis. In vitro, IL-8 promoted ovarian cancer cell migration, initiated the epithelial-mesenchymal transition (EMT) program and activated Wnt/β-catenin signalling. However, when treated with Reparixin (inhibitor of both IL-8 receptors CXCR1 and CXCR2), effect of both endogenous and exogenous IL-8 was reversed. Together, our results indicated that IL-8 triggered ovarian cancer cells migration partly through Wnt/β-catenin pathway mediated EMT, and IL-8 may be an important molecule in the invasion and metastasis of ovarian cancer.

Citing Articles

Enhanced Expression of TRIM46 in Ovarian Cancer Cells Induced by Tumor-Associated Macrophages Promotes Invasion via the Wnt/β-Catenin Pathway.

Wang Y, Choi M, Kim J, Choi J Cells. 2025; 14(3).

PMID: 39937005 PMC: 11817100. DOI: 10.3390/cells14030214.

A common secretomic signature across epithelial cancers metastatic to the pleura supports IL-6 axis therapeutic targeting.

Donnenberg V, Luketich J, Popov B, Bartlett D, Donnenberg A Front Immunol. 2024; 15:1404373.

PMID: 39114667 PMC: 11303180. DOI: 10.3389/fimmu.2024.1404373.

Intracerebellar administration of the chemokine Cxcl3 reduces the volume of medulloblastoma lesions at an advanced stage by promoting the migration and differentiation of preneoplastic precursor cells.

Ceccarelli M, Rossi S, Bonaventura F, Massari R, DElia A, Soluri A Brain Pathol. 2024; 35(1):e13283.

PMID: 38946128 PMC: 11669415. DOI: 10.1111/bpa.13283.

Repositioning of antiarrhythmics for prostate cancer treatment: a novel strategy to reprogram cancer-associated fibroblasts towards a tumor-suppressive phenotype.

Doldi V, Tortoreto M, Colecchia M, Maffezzini M, Percio S, Giammello F J Exp Clin Cancer Res. 2024; 43(1):161.

PMID: 38858661 PMC: 11165820. DOI: 10.1186/s13046-024-03081-0.

Anti-IL-8 monoclonal antibodies inhibits the autophagic activity and cancer stem cells maintenance within breast cancer tumor microenvironment.

Abou Shousha S, M Osman E, Baheeg S, Shahine Y Breast Dis. 2024; 43(1):37-49.

PMID: 38552109 PMC: 10977415. DOI: 10.3233/BD-230052.

References

Chao T, Yo Y, Liao Y, Wang Y, Su P, Huang T . LIM-homeobox transcription factor 1, alpha (LMX1A) inhibits tumourigenesis, epithelial-mesenchymal transition and stem-like properties of epithelial ovarian cancer. Gynecol Oncol. 2012; 128(3):475-82. DOI: 10.1016/j.ygyno.2012.12.018. View

Wang B, Tang Z, Gong H, Zhu L, Liu X . Wnt5a promotes epithelial-to-mesenchymal transition and metastasis in non-small-cell lung cancer. Biosci Rep. 2017; 37(6). PMC: 5705780. DOI: 10.1042/BSR20171092. View

Dai C, Xie Y, Zhuang X, Yuan Z . MiR-206 inhibits epithelial ovarian cancer cells growth and invasion via blocking c-Met/AKT/mTOR signaling pathway. Biomed Pharmacother. 2018; 104:763-770. DOI: 10.1016/j.biopha.2018.05.077. View

Kisielewski R, Tolwinska A, Mazurek A, Laudanski P . Inflammation and ovarian cancer--current views. Ginekol Pol. 2013; 84(4):293-7. DOI: 10.17772/gp/1579. View

Hidaka H, Ishiko T, Furuhashi T, Kamohara H, Suzuki S, Miyazaki M . Curcumin inhibits interleukin 8 production and enhances interleukin 8 receptor expression on the cell surface:impact on human pancreatic carcinoma cell growth by autocrine regulation. Cancer. 2002; 95(6):1206-14. DOI: 10.1002/cncr.10812. View

Wang T, Liang J, Xiang X, Yuan J, Chen X, Xiang X . Functional identification and expressional responses of large yellow croaker (Larimichthys crocea) interleukin-8 and its receptor. Fish Shellfish Immunol. 2019; 87:470-477. DOI: 10.1016/j.fsi.2019.01.035. View

Agarwal A, Tressel S, Kaimal R, Balla M, Lam F, Covic L . Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy. Cancer Res. 2010; 70(14):5880-90. PMC: 2917243. DOI: 10.1158/0008-5472.CAN-09-4341. View

Browne A, Sriraksa R, Guney T, Rama N, Van Noorden S, Curry E . Differential expression of IL-8 and IL-8 receptors in benign, borderline and malignant ovarian epithelial tumours. Cytokine. 2013; 64(1):413-21. DOI: 10.1016/j.cyto.2013.05.006. View

Waugh D, Wilson C . The interleukin-8 pathway in cancer. Clin Cancer Res. 2008; 14(21):6735-41. DOI: 10.1158/1078-0432.CCR-07-4843. View

10.

Lim J, Thiery J . Epithelial-mesenchymal transitions: insights from development. Development. 2012; 139(19):3471-86. DOI: 10.1242/dev.071209. View

11.

Boon E, van der Neut R, van de Wetering M, Clevers H, Pals S . Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res. 2002; 62(18):5126-8. View

12.

Kanzawa M, Semba S, Hara S, Itoh T, Yokozaki H . WNT5A is a key regulator of the epithelial-mesenchymal transition and cancer stem cell properties in human gastric carcinoma cells. Pathobiology. 2013; 80(5):235-44. DOI: 10.1159/000346843. View

13.

Wen J, Zhao Z, Huang L, Wang L, Miao Y, Wu J . IL-8 promotes cell migration through regulating EMT by activating the Wnt/β-catenin pathway in ovarian cancer. J Cell Mol Med. 2019; 24(2):1588-1598. PMC: 6991660. DOI: 10.1111/jcmm.14848. View

14.

Martins-Filho A, Jammal M, Micheli D, Tavares-Murta B, Etchebehere R, Murta E . Role of Intracystic Cytokines and Nitric Oxide in Ovarian Neoplasms. Scand J Immunol. 2017; 86(6):462-470. DOI: 10.1111/sji.12617. View

15.

Chung V, Tan T, Huang R, Lai H, Huang R . Loss of discoidin domain receptor 1 (DDR1) via CpG methylation during EMT in epithelial ovarian cancer. Gene. 2017; 635:9-15. DOI: 10.1016/j.gene.2017.09.001. View

16.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

17.

Davidson B, Trope C, Reich R . Epithelial-mesenchymal transition in ovarian carcinoma. Front Oncol. 2012; 2:33. PMC: 3356037. DOI: 10.3389/fonc.2012.00033. View

18.

Yang G, Rosen D, Liu G, Yang F, Guo X, Xiao X . CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res. 2010; 16(15):3875-86. PMC: 2930833. DOI: 10.1158/1078-0432.CCR-10-0483. View

19.

Yeung T, Leung C, Wong K, Gutierrez-Hartmann A, Kwong J, Gershenson D . ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells. Oncotarget. 2017; 8(10):16951-16963. PMC: 5370013. DOI: 10.18632/oncotarget.15208. View

20.

Cohen C, Shea A, Heffron C, Schmelz E, Roberts P . The parity-associated microenvironmental niche in the omental fat band is refractory to ovarian cancer metastasis. Cancer Prev Res (Phila). 2013; 6(11):1182-93. PMC: 3836366. DOI: 10.1158/1940-6207.CAPR-13-0227. View